본문 바로가기
KERD
논문KCI 등재

Ethnic Differences in the Safety and Efficacy of Tenecteplase Versus Alteplase for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis

Vijay Kumar Sharma|Ching-Hui Sia|Jin Hean Koh|Claire Yi Jia Lim|Lucas Tze Peng Tan|Kian Keong Poh|Leonard Leong Litt Yeo|Andrew Fu Wah Ho|Teddy Wu|William Kok-Fai Kong|Benjamin Yong Qiang Tan
대한뇌졸중학회 (The Korean Stroke Society)|2024.09|대한뇌졸중영문학회지 (Journal of stroke)|제26권 제3호|pp. 371-390

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

BrainAcute strokeIschemic strokeThrombolysis
주제분류신경과학

초록

Background and Purpose Tenecteplase is a thrombolytic agent with pharmacological advantages over alteplase and has been shown to be noninferior to alteplase for acute ischemic stroke in randomized trials. However, evidence pertaining to the safety and efficacy of tenecteplase in patients from different ethnic groups is lacking. The aim of this systematic review and metaanalysis was to investigate ethnicity-specific differences in the safety and efficacy of tenecteplase versus alteplase in patients with acute ischemic stroke. Methods Following an International Prospective Register of Systematic Reviews (PROSPERO)- registered protocol (CRD42023475038), three authors conducted a systematic review of the PubMed/MEDLINE, Embase, Cochrane Library, and CINAHL databases for articles comparing the use of tenecteplase with any thrombolytic agent in patients with acute ischemic stroke up to November 20, 2023. The certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Two independent authors extracted data onto a standardized data collection sheet. A pairwise meta-analysis was conducted in risk ratios (RR). Results From 34 studies (59,601 participants), the rate of complete recanalization was significantly higher (P<0.01) in Asian (RR: 1.91, 95% confidence interval [CI]: 1.30 to 2.80) versus Caucasian patients (RR: 0.99, 95% CI: 0.87 to 1.14). However, Asian patients (RR: 1.18, 95% CI: 0.87 to 1.62) had significantly higher (P=0.01) rates of mortality compared with Caucasian patients (RR: 1.10, 95% CI: 1.00 to 1.22). Caucasian patients were also more likely to attain a modified Rankin Scale (mRS) score of 0 to 2 at follow-up (RR: 1.14, 95% CI, 1.10 to 1.19) compared with Asian (RR: 1.00, 95% CI, 0.95 to 1.05) patients. There was no significant difference in the rate of symptomatic intracranial hemorrhage (P=0.20) and any intracranial hemorrhage (P=0.83) between Asian and Caucasian patients. Conclusion Tenecteplase was associated with significantly higher rates of complete recanalization in Asian patients compared with Caucasian patients. However, tenecteplase was associated with higher rates of mortality and lower rates of mRS 0 to 2 in Asian patients compared with Caucasian patients. It may be beneficial to study the variations in response to tenecteplase among patients of different ethnic groups in large prospective cohort studies.

Abstract

Background and Purpose Tenecteplase is a thrombolytic agent with pharmacological advantages over alteplase and has been shown to be noninferior to alteplase for acute ischemic stroke in randomized trials. However, evidence pertaining to the safety and efficacy of tenecteplase in patients from different ethnic groups is lacking. The aim of this systematic review and metaanalysis was to investigate ethnicity-specific differences in the safety and efficacy of tenecteplase versus alteplase in patients with acute ischemic stroke. Methods Following an International Prospective Register of Systematic Reviews (PROSPERO)- registered protocol (CRD42023475038), three authors conducted a systematic review of the PubMed/MEDLINE, Embase, Cochrane Library, and CINAHL databases for articles comparing the use of tenecteplase with any thrombolytic agent in patients with acute ischemic stroke up to November 20, 2023. The certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Two independent authors extracted data onto a standardized data collection sheet. A pairwise meta-analysis was conducted in risk ratios (RR). Results From 34 studies (59,601 participants), the rate of complete recanalization was significantly higher (P<0.01) in Asian (RR: 1.91, 95% confidence interval [CI]: 1.30 to 2.80) versus Caucasian patients (RR: 0.99, 95% CI: 0.87 to 1.14). However, Asian patients (RR: 1.18, 95% CI: 0.87 to 1.62) had significantly higher (P=0.01) rates of mortality compared with Caucasian patients (RR: 1.10, 95% CI: 1.00 to 1.22). Caucasian patients were also more likely to attain a modified Rankin Scale (mRS) score of 0 to 2 at follow-up (RR: 1.14, 95% CI, 1.10 to 1.19) compared with Asian (RR: 1.00, 95% CI, 0.95 to 1.05) patients. There was no significant difference in the rate of symptomatic intracranial hemorrhage (P=0.20) and any intracranial hemorrhage (P=0.83) between Asian and Caucasian patients. Conclusion Tenecteplase was associated with significantly higher rates of complete recanalization in Asian patients compared with Caucasian patients. However, tenecteplase was associated with higher rates of mortality and lower rates of mRS 0 to 2 in Asian patients compared with Caucasian patients. It may be beneficial to study the variations in response to tenecteplase among patients of different ethnic groups in large prospective cohort studies.

참고문헌 (58)

  1. Huang X, "Alteplase versus tenecteplase for thrombolysis after ischaemic stroke(ATTEST) : a phase 2, randomised, open-label, blinded endpoint study", Lancet Neurol, 14, pp.368~376 (2015)
  2. Menon BK, "Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada(AcT) : a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial", Lancet, 400, pp.161~169 (2022)
  3. Kvistad CE, "Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway(NOR-TEST 2, part A) : a phase 3, randomised, open-label, blinded endpoint, noninferiority trial", Lancet Neurol, 21, pp.511~519 (2022)
  4. Wang Y, "Tenecteplase versus alteplase in acute ischaemic cerebrovascular events(TRACE-2) : a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial", Lancet, 401, pp.645~654 (2023)
  5. Muir K, "Abstract TMP24 : alteplase-tenecteplase trial evaluation for stroke thrombolysis(ATTEST 2)", Stroke, 49(Suppl 1), pp.ATMP24~ (2018)
  6. Parsons M, "A randomized trial of tenecteplase versus alteplase for acute ischemic stroke", N Engl J Med, 366, pp.1099~1107 (2012)
  7. Chandra A, "Efficacy outcomes of tenecteplase versus alteplase in patients with ischemic stroke in therapeutic window : experience from a single institution", Arch Med Health Sci, 11, pp.3~8 (2023)
  8. George M, "Comparison of thrombolytic agents in treatment of patients with acute ischemic stroke; findings from a single centre follow up study in real-life settings", J Clin Neurosci, 91, pp.299~305 (2021)
  9. Li S, "Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke(TRACE) : a multicentre, randomised, open label, blinded-endpoint(PROBE)controlled phase II study", Stroke Vasc Neurol, 7, pp.47~53 (2022)
  10. Warach SJ, "Symptomatic intracranial hemorrhage with tenecteplase vs alteplase in patients with acute ischemic stroke : the comparative effectiveness of routine tenecteplase vs alteplase in acute ischemic stroke(CERTAIN)collaboration", JAMA Neurol, 80, pp.732~738 (2023)
  11. Saaiq M, "Modifying"pico"question into"picos"model for more robust and reproducible presentation of the methodology employed in a scientific study", World J Plast Surg, 6, pp.390~392 (2017)
  12. Schardt C, "Utilization of the PICO framework to improve searching PubMed for clinical questions", BMC Med Inform Decis Mak, 7, pp.16~ (2007)
  13. Sterne JAC, "RoB 2 : a revised tool for assessing risk of bias in randomised trials", BMJ, 366, pp.l4898~ (2019)
  14. Sterne JA, "ROBINS-I : a tool for assessing risk of bias in non-randomised studies of interventions", BMJ, 355, pp.i4919~ (2016)
  15. Sterne JA, "Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials", BMJ, 343, pp.d4002~ (2011)
  16. Egger M, "Bias in meta-analysis detected by a simple, graphical test", BMJ, 315, pp.629~634 (1997)
  17. Balduzzi S, "How to perform a metaanalysis with R : a practical tutorial", Evid Based Ment Health, 22, pp.153~160 (2019)
  18. Wan X, "Estimating the sample mean and standard deviation from the sample size, median, range and", or interquartile range, 2014, pp.14, 135~
  19. Higgins JP, "Measuring inconsistency in meta-analyses", BMJ, 327, pp.557~560 (2003)
  20. Fletcher J, "What is heterogeneity and is it important?", BMJ, 334, pp.94~96 (2007)
  21. Tufanaru C, "Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness", Int J Evid Based Healthc, 13, pp.196~207 (2015)
  22. Riley RD, "Interpretation of random effects meta-analyses", BMJ, 342, pp.d549~ (2011)
  23. Deeks JJ, "Cochrane handbook for systematic reviews of interventions", pp.241~284 (2019), Wiley
  24. Thompson SG, "How should meta-regression analyses be undertaken and interpreted?", Stat Med, 21, pp.1559~1573 (2002)
  25. Higgins JP, "Controlling the risk of spurious findings from meta-regression", Stat Med, 23, pp.1663~1682 (2004)
  26. Guyatt GH, "GRADE : an emerging consensus on rating quality of evidence and strength of recommendations", BMJ, 336, pp.924~926 (2008)
  27. Bivard A, "Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne mobile stroke unit(TASTE-A) : a phase 2, randomised, open-label trial", Lancet Neurol, 21, pp.520~527 (2022)
  28. Campbell BCV, "Tenecteplase versus alteplase before thrombectomy for ischemic stroke", N Engl J Med, 378, pp.1573~1582 (2018)
  29. Checkouri T, "Early recanalization among patients undergoing bridging therapy with tenecteplase or alteplase", Stroke, 54, pp.2491~2499 (2023)
  30. Dhar N, "Tenecteplase and alteplase for thrombolysis of acute ischemic stroke within 4. 5 hours : an efficacy and safety study", Ann Indian Acad Neurol, 25, pp.897~901 (2022)
  31. Estella Á, "Effectiveness and safety of tecneplase vs. alteplase in the acute treatment of ischemic stroke", J Pers Med, 12, pp.1525~ (2022)
  32. Gerschenfeld G, "Treatment times, functional outcome, and hemorrhage rates after switching to tenecteplase for stroke thrombolysis : insights from the TETRIS registry", Eur Stroke J, 7, pp.358~364 (2022)
  33. Haley EC Jr, "Phase IIB", III trial of tenecteplase in acute ischemic stroke : results of a prematurely terminated randomized clinical trial, 2010, pp.41, 707~711
  34. Hall J, "Tenecteplase improves door-to-needle time in real-world acute stroke treatment", Stroke Vasc Interv Neurol, 1, pp.e000102~ (2021)
  35. Hendrix P, "Tenecteplase versus alteplase before mechanical thrombectomy : experience from a US healthcare system undergoing a system-wide transition of primary thrombolytic", J Neurointerv Surg, 15, pp.e277~e281 (2023)
  36. Kuruttukulam G, "Does tenecteplase before mechanical thrombectomy result in a faster revascularization as compared to alteplase? Observations from a comprehensive stroke care center in Southern India", J Stroke Med, 6, pp.40~45 (2023)
  37. Logallo N, "Tenecteplase versus alteplase for management of acute ischaemic stroke(NOR-TEST) : a phase 3, randomised, open-label, blinded endpoint trial", Lancet Neurol, 16, pp.781~788 (2017)
  38. Mahawish K, "Switching to tenecteplase for stroke thrombolysis : real-world experience and outcomes in a regional stroke network", Stroke, 52, pp.e590~e593 (2021)
  39. Mohan A, "Biosimilar tenecteplase versus alteplase in acute ischemic stroke : a real world study", Ann Indian Acad Neurol, 26, pp.54~58 (2023)
  40. Murphy LR, "Tenecteplase versus alteplase for acute stroke : mortality and bleeding complications", Ann Emerg Med, 82, pp.720~728 (2023)
  41. Parsons MW, "Acute ischemic stroke : imaging-guided tenecteplase treatment in an extended time window", Neurology, 72, pp.915~921 (2009)
  42. Psychogios K, "Real-world comparative safety and efficacy of tenecteplase versus alteplase in acute ischemic stroke patients with large vessel occlusion", Ther Adv Neurol Disord, 14, pp.1756286420986727~ (2021)
  43. Qureshi AI, "Outcomes with IV tenecteplase and IV alteplase for acute ischemic stroke with or without thrombectomy in realworld settings in the United States", J Stroke Cerebrovasc Dis, 32, pp.106898~ (2023)
  44. Sjögren V, "Feasibility of switching from alteplase to tenecteplase for stroke thrombolysis–a retrospective cohort analysis", IBRO Neurosci Rep, 14, pp.353~357 (2023)
  45. Sundar K, "Tenecteplase versus alteplase(TENVALT) : a study comparing two thrombolytic agents in acute ischemic stroke", Neurol Asia, 24, pp.203~208 (2019)
  46. Teivane A, "Tenecteplase or alteplase better in patients with acute ischemic stroke due to large vessel occlusion : a single center observational study", Medicina(Kaunas), 58, pp.1169~ (2022)
  47. Tsivgoulis G, "Intravenous thrombolysis with tenecteplase for the treatment of acute ischemic stroke", Ann Neurol, 92, pp.349~357 (2022)
  48. Walton MN, "Major bleeding postadministration of tenecteplase versus alteplase in acute ischemic stroke", Ann Pharmacother, 57, pp.535~543 (2023)
  49. Warach SJ, "Prospective observational cohort study of tenecteplase versus alteplase in routine clinical practice", Stroke, 53, pp.3583~3593 (2022)
  50. Zhao ZA, "Intraarterial tenecteplase is safe and may improve the first-pass recanalization for acute ischemic stroke with large-artery atherosclerosis : the BRETIS-TNK trial", Front Neurol, 14, pp.1155269~ (2023)
  51. Zhong CS, "Routine use of tenecteplase for thrombolysis in acute ischemic stroke", Stroke, 52, pp.1087~1090 (2021)
  52. McHugh ML, "Interrater reliability : the kappa statistic", Biochem Med(Zagreb), 22, pp.276~282 (2012)
  53. Hacke W, "Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke(ECASS II)", Lancet, 352, pp.1245~1251 (1998)
  54. Wahlgren N, "Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in strokemonitoring study(SITS-MOST) : an observational study", Lancet, 369, pp.275~282 (2007)
  55. Tsai CF, "Risk factors for ischemic stroke and its subtypes in Chinese vs. Caucasians : systematic review and meta-analysis", Int J Stroke, 10, pp.485~493 (2015)
  56. Katsanos AH, "Off-label use of tenecteplase for the treatment of acute ischemic stroke : a systematic review and meta-analysis", JAMA Netw Open, 5, pp.e224506~ (2022)
  57. Rose D, "Complications of intravenous tenecteplase versus alteplase for the treatment of acute ischemic stroke : a systematic review and meta-analysis", Stroke, 54, pp.1192~1204 (2023)
  58. Katsanos AH, "Intravenous thrombolysis with tenecteplase in patients with large vessel occlusions : systematic review and metaanalysis", Stroke, 52, pp.308~312 (2021)

관련 논문AI추천

Tenecteplase Beyond 4.5 Hours in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Clinical TrialsAbdullah Hamad, Ekaterina Bakradze, Fatema Ahmad Alhnidi, Felicia Hataway, Michael J. Lyerly, Mohamed Elfil, Mohammad Aladawi, Mohammad J. J. Taha, Mohammad T. Abuawwad, Warda A. Alrubasy, Xiaohan Peng, Yasmeena Abdelall Kozaa, Zaid Najdawi대한뇌졸중학회 · 대한뇌졸중영문학회지2025 · 제27권 제2호Replacing Alteplase with Tenecteplase: Is the Time Ripe?Adam A. Dmytriw, Aravind Ganesh, Bijoy K. Menon, Joshua A. Hirsch, Nishita Singh, Robert W. Regenhardt대한뇌졸중학회 · 대한뇌졸중영문학회지2023 · 제25권 제1호Tenecteplase Versus Alteplase in Medium Vessel Occlusion Ischemic Stroke: A Secondary Analysis of the Alteplase Compared to Tenecteplase Randomized TrialAleksander Tkach, Anas Alrohimi, Andrew Demchuk, Ayoola Ademola, Bijoy K. Menon, Brian Buck, Dariush Dowlatshahi, Faysal Benali, Fouzi Bala, Gary Hunter, Houman Khosravani, Ibrahim Alhabli, Katrina Ignacio, Luciana Catanese, MacKenzie Horn, Michael Hill, Mohammed Almekhlafi, Nishita Singh, Richard Swartz, Thalia Field, Tolulope Sajobi대한뇌졸중학회 · 대한뇌졸중영문학회지2024 · 제26권 제2호Tenecteplase in Acute Ischemic Stroke: A Scientific Statement From the Korean Stroke SocietyAndrew M. Demchuk, Beom Joon Kim, Chulho Kim, Dae-Hyun Kim, Dong-Eog Kim, Hee-Joon Bae, Hyunsoo Kim, Jay Chol Choi, Joon-Tae Kim, Mark W Parsons, Masatoshi Koga, Philip B. Gorelick대한신경과학회 · Journal of Clinical Neurology2025 · 제21권 제5호Intravenous Tenecteplase for Acute Ischemic Stroke Within 4.5–24 Hours of Onset (ROSE-TNK): A Phase 2, Randomized, Multicenter StudyChen Hui-Sheng, Cui Yu, Dai Ying-Jie, Duan Ying-Jie, Feng Ye-Fang, Geng Shi-Mei, Jiang Chang-Hao, Lu Jiang, Ma Yu-Tong, Song Cheng-Guang, Wang Lu, Zhang Hong, Zhang Ping, Zhang Yi, Zhang Zai-Hui, Zhao Hang, Zhao Li-Wei, Zhao Yong대한뇌졸중학회 · 대한뇌졸중영문학회지2023 · 제25권 제3호Endovascular Recanalization Therapy in Acute Ischemic Stroke: Updated Meta-analysis of Randomized Controlled Trials고상배, 나정호, 유경호, 이지성, 홍근식대한뇌졸중학회 · 대한뇌졸중영문학회지2015 · 제17권 제3호

이 간행물의 다른 논문 (12건)

Patent Foramen Ovale and Other Cardiopathies as Causes of Embolic Stroke With Unknown SourceJong S. Kimpp. 349-359Ruptured Peripheral Cerebral Aneurysms Associated With Moyamoya Disease: A Systematic ReviewChao Fu, Yongquan Chang, Zheng Fengpp. 360-370Carbonated Beverage, Fruit Drink, and Water Consumption and Risk of Acute Stroke: the INTERSTROKE Case-Control StudyFernando Lanas, Danuta Ryglewicz, Catriona Reddin, Annika Rosengren, Salim Yusuf, Martin O’Donnell, Xingyu Wang, Anna Czlonkowska, Andrew Smyth, Graeme J. Hankey, Albertino Damasceno, Helle Klingenberg Iversen, Shahram Oveisgharan, Fawaz Alhussain, Peter Langhorne, Dennis Xavier, Patricio Lopez Jaramillo, Aytekin Oguz, Clodagh McDermottpp. 391-402Early Neurological Deterioration and Time to Start Dual Antiplatelet Therapy in Patients With Acute Mild-to-Moderate Ischemic Stroke: A Pre-Specified Post Hoc Analysis of the ATAMIS TrialHui-Sheng Chen, Zhi-Guo Yao, Yu Cui, Jian Zhangpp. 403-414Early Improvement in Interstitial Fluid Flow in Patients With Severe Carotid Stenosis After Angioplasty and StentingShih-Pin Chen, Kai-Wei Yu, Te-Ming Lin, Chao-Bao Luo, Feng-Chi Chang, Jiing-Feng Lirng, Chih-Ping Chung, I-Hui Lee, Chia-Hung Wupp. 415-424
원문 보기